IP Risks Loom Over Ekso Bionics: Patent Disputes, Shared Ownership, and Threats to Future Growth

Ekso Bionics Holding (EKSO) has disclosed a new risk, in the Trade Secrets category.

Ekso Bionics Holding operates in an IP-intensive medical device sector where infringement and misappropriation claims are common and costly, potentially diverting management focus and constraining product sales. Its reliance on co-owned patents with UC Berkeley, some of which are licensed to third parties or not exclusively licensed to Ekso, heightens litigation risk, royalty burdens, and uncertainty over long-term control of critical technologies.

A successful infringement action against Ekso Bionics Holding could lead to substantial damages, adverse licensing terms, or injunctions limiting key product lines and future innovations. At the same time, enforcing its own patents may trigger counterclaims, narrow or invalidate existing protections, expose confidential information through discovery, and ultimately undermine the value of its intellectual property portfolio.

Overall, Wall Street has a Hold consensus rating on EKSO stock based on 1 Hold.

To learn more about Ekso Bionics Holding’s risk factors, click here.